165,426 Shares in Inogen, Inc. (NASDAQ:INGN) Purchased by Invenomic Capital Management LP

Invenomic Capital Management LP purchased a new position in Inogen, Inc. (NASDAQ:INGNGet Rating) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 165,426 shares of the medical technology company’s stock, valued at approximately $5,624,000. Inogen makes up 1.2% of Invenomic Capital Management LP’s investment portfolio, making the stock its 23rd largest holding.

A number of other large investors have also bought and sold shares of INGN. Nisa Investment Advisors LLC raised its position in Inogen by 64.1% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,280 shares of the medical technology company’s stock worth $38,000 after purchasing an additional 500 shares in the last quarter. Macquarie Group Ltd. raised its position in Inogen by 383.9% in the third quarter. Macquarie Group Ltd. now owns 1,079 shares of the medical technology company’s stock worth $46,000 after purchasing an additional 856 shares in the last quarter. Point72 Hong Kong Ltd acquired a new position in Inogen in the third quarter worth about $81,000. Royal Bank of Canada raised its position in Inogen by 17.8% in the third quarter. Royal Bank of Canada now owns 4,126 shares of the medical technology company’s stock worth $177,000 after purchasing an additional 622 shares in the last quarter. Finally, Perkins Capital Management Inc. acquired a new position in Inogen in the fourth quarter worth about $228,000. 96.01% of the stock is owned by hedge funds and other institutional investors.

In other news, Director Ray Benjamin M. Anderson sold 4,516 shares of the stock in a transaction that occurred on Thursday, March 3rd. The shares were sold at an average price of $34.68, for a total transaction of $156,614.88. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.29% of the stock is owned by corporate insiders.

Shares of NASDAQ INGN traded up $0.21 during mid-day trading on Friday, hitting $24.96. 156,800 shares of the stock were exchanged, compared to its average volume of 200,441. The company has a market cap of $570.09 million, a P/E ratio of -28.36 and a beta of 1.01. The stock’s fifty day simple moving average is $28.94 and its two-hundred day simple moving average is $31.01. Inogen, Inc. has a twelve month low of $22.51 and a twelve month high of $82.35.

Inogen (NASDAQ:INGNGet Rating) last released its quarterly earnings results on Thursday, May 5th. The medical technology company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.15). Inogen had a negative net margin of 5.64% and a negative return on equity of 3.83%. The company had revenue of $80.39 million for the quarter, compared to the consensus estimate of $76.56 million. During the same period last year, the company earned ($0.03) earnings per share. Inogen’s revenue for the quarter was down 7.5% compared to the same quarter last year. Analysts forecast that Inogen, Inc. will post -1.63 EPS for the current year.

Several research analysts recently issued reports on INGN shares. TheStreet lowered shares of Inogen from a “c-” rating to a “d” rating in a research report on Friday, March 11th. Stifel Nicolaus dropped their price objective on shares of Inogen from $40.00 to $30.00 in a report on Monday, May 9th. Finally, StockNews.com lowered shares of Inogen from a “hold” rating to a “sell” rating in a report on Thursday, May 12th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, Inogen currently has a consensus rating of “Hold” and a consensus price target of $41.00.

About Inogen (Get Rating)

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Featured Stories

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen, Inc. (NASDAQ:INGNGet Rating).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.